What does Shanghai Henlius Biotech do?

Henlius develops and sells biologic medicines, which are drugs made from living cells, such as antibodies. Its products mainly treat cancers like breast, colorectal, gastric and lung cancer, as well as autoimmune conditions like rheumatoid arthritis and Crohn's disease. It is also developing drugs for eye disease, lung fibrosis, osteoporosis and blood cancer.

Healthcare · Biotechnology · 2696.HK

What Shanghai Henlius Biotech Does & How It Makes Money (2696.HK)

Updated October 2026 · reflects Shanghai Henlius Biotech's latest reported financials

Chinese biotech developing biosimilar and innovative antibody drugs for cancer and immune diseases. It makes money by selling approved antibody injections, including biosimilar versions of established drugs such as trastuzumab, adalimumab, bevacizumab and rituximab, along with its own anti-PD-1 drug serplulimab.

Shanghai Henlius Biotech's story, moat and numbers — in a 3-minute visual book.

Explore Shanghai Henlius Biotech on TacticScale →

How Shanghai Henlius Biotech makes money

It makes money by selling approved antibody injections, including biosimilar versions of established drugs such as trastuzumab, adalimumab, bevacizumab and rituximab, along with its own anti-PD-1 drug serplulimab. It sells in Mainland China and in markets across Asia Pacific, the Americas, Europe and Oceania.

What Shanghai Henlius Biotech does

Shanghai Henlius Biotech, founded in 2010 and headquartered in Shanghai, develops biologic medicines for cancer, autoimmune diseases and eye diseases. Several of its marketed products are antibody injections based on established drugs: HANQUYOU (trastuzumab) for breast and gastric cancer, HANBEITAI (bevacizumab) for colorectal and lung cancer, HANDAYUAN (adalimumab) for rheumatoid arthritis, psoriasis, Crohn's disease and other immune conditions, and HANLIKANG (rituximab). It also has HANSIZHUANG (serplulimab), an anti-PD-1 immunotherapy used for colorectal cancer, gastric cancer and limited-stage small cell lung cancer. Its pipeline includes HLX04-O for wet age-related macular degeneration, HLX22 for gastric and gastroesophageal junction cancer, HLX6018 for idiopathic pulmonary fibrosis, HLX42, HLX43 and HLX53 for solid tumors, HLX11 for breast cancer, HLX14 for osteoporosis and HLX15 for multiple myeloma. The company operates in Mainland China, Asia Pacific, the Americas, Europe and Oceania. It is a subsidiary of Shanghai Fosun Pharmaceutical Development Co., Ltd.

Products & services

HANQUYOU (trastuzumab)
HANSIZHUANG (serplulimab)
HANDAYUAN (adalimumab)
HANBEITAI (bevacizumab)
HANLIKANG (rituximab)
HLX22

What is Shanghai Henlius Biotech worth?

Fair value: not published

A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.

We show a fair value only when the method is trustworthy. See Shanghai Henlius Biotech on TacticScale →

Sector Healthcare Industry Biotechnology HQ China Ticker 2696.HK Official site

Related companies

Bio-Thera Solutions (688177.SS) · Shanghai Junshi Biosciences (688180.SS) · Hualan Biological Engineering (002007.SZ)

Understand Shanghai Henlius Biotech in 3 minutes →